Scarica l'app Stockscreener
53.97
3.62%
-2.03
Dopo l'orario di chiusura:
54.00
0.03
+0.06%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$56.00
Aprire:
$56
Volume 24 ore:
1.77M
Relative Volume:
1.15
Capitalizzazione di mercato:
$8.26B
Reddito:
$700.35M
Utile/perdita netta:
$461.90M
Rapporto P/E:
18.81
EPS:
2.8696
Flusso di cassa netto:
$-14.19M
1 W Prestazione:
-2.53%
1M Prestazione:
-3.37%
6M Prestazione:
+57.35%
1 anno Prestazione:
+54.77%
Intervallo 1D:
$53.66
$56.24
Intervallo di 1 settimana:
$53.36
$56.83
Portata 52W:
$26.76
$59.30
Tg Therapeutics Inc Stock (TGTX) Company Profile
Nome
Tg Therapeutics Inc
Settore
Industria
Telefono
(212) 554-4484
Indirizzo
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
53.97 | 8.26B | 700.35M | 461.90M | -14.19M | 2.8696 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-06 | Ripresa | H.C. Wainwright | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2024-10-29 | Iniziato | TD Cowen | Buy |
| 2023-08-02 | Aggiornamento | Goldman | Sell → Neutral |
| 2023-06-26 | Ripresa | Jefferies | Buy |
| 2022-05-20 | Iniziato | BofA Securities | Underperform |
| 2022-02-23 | Reiterato | B. Riley Securities | Buy |
| 2021-11-15 | Downgrade | Goldman | Neutral → Sell |
| 2021-04-20 | Iniziato | Goldman | Neutral |
| 2021-04-19 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-01 | Iniziato | JP Morgan | Overweight |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-05 | Iniziato | Evercore ISI | Outperform |
| 2020-01-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-27 | Ripresa | B. Riley FBR | Buy |
| 2019-02-06 | Ripresa | Jefferies | Buy |
| 2018-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Ripresa | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Ripresa | H.C. Wainwright | Buy |
| 2017-04-25 | Iniziato | Jefferies | Buy |
| 2017-03-06 | Reiterato | FBR & Co. | Outperform |
| 2016-10-06 | Ripresa | Brean Capital | Buy |
| 2016-05-27 | Iniziato | SunTrust | Buy |
| 2015-12-01 | Iniziato | FBR Capital | Outperform |
| 2015-09-09 | Iniziato | Raymond James | Strong Buy |
| 2015-08-12 | Ripresa | H.C. Wainwright | Buy |
| 2015-06-19 | Reiterato | Brean Capital | Buy |
| 2014-12-11 | Reiterato | ROTH Capital | Buy |
| 2014-12-10 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tg Therapeutics Inc Borsa (TGTX) Ultime notizie
TGTX Stock Rises 60% in 6 Months: Here's What You Should Know - Zacks Investment Research
TGTX Stock Rises 60% in 6 Months: Here's What You Should Know - TradingView
Thermo Fisher to Report Q3 Earnings: What's in the Cards? - Zacks Investment Research
TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis - BioSpace
TG Therapeutics (TGTX) Reports Five-Year Study Showing BRIUMVI's - GuruFocus
TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis - Business Wire
High Growth Tech Stocks To Watch In US October 2026 - Simply Wall Street
How TG’s MS Data Wave At MSToronto2026 At TG Therapeutics (TGTX) Has Changed Its Investment Story - Yahoo Finance
TG Therapeutics (TGTX) Stock May Be Undervalued Despite Fresh Newsflow - Yahoo Finance
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026 - BioSpace
TG Therapeutics (TGTX) to Present Phase 1 Azer-cel Data and BRIU - GuruFocus
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026 - Business Wire
TG Therapeutics, Inc. (TGTX) Stock Forecasts - Yahoo Finance
TG Therapeutics, Inc. (TGTX) Stock forecasts - Yahoo Finance Singapore
TG Therapeutics (NASDAQ:TGTX) Emerges as an Affordable Growth Play in Biotech - ChartMill
TG Therapeutics, Inc. (TGTX) Stock Forecasts - Yahoo Finance
TG Therapeutics, Inc. (TGTX) Stock forecasts - Yahoo Finance Australia
TG Therapeutics, Inc. (TGTX) Stock Forecasts - Yahoo Finance
TG Therapeutics, Inc. (TGTX) Stock forecasts - Yahoo Finance Australia
After tax other income/expense of TG Therapeutics, Inc. – HAN:NKB2 - TradingView
TG Therapeutics, Inc. Revenue Breakdown – HAN:NKB2 - TradingView
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm - Morningstar
TG Therapeutics (NasdaqCM:TGTX) Stock Forecast & Analyst Predictions - Simply Wall Street
TG Therapeutics, Inc. (TGTX) Stock Forecasts - Yahoo! Finance Canada
TG Therapeutics, Inc. (TGTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
TG Therapeutics (NASDAQ:TGTX) Combines Strong Growth With a Tight Technical Breakout Setup - ChartMill
TG Therapeutics, Inc. (TGTX) Stock Analysis: Exploring a 22.59% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
TG Therapeutics Inc (TGTX) Stock Price Today: $56.87 - Pluang
TG Therapeutics Inc (TGTX) Stock Price, Quote, News & History - benzinga.com
TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share - Yahoo Finance
TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share - TradingView
TG Therapeutics (TGTX) Could Be 19% Undervalued After Its Recent Rebound - Yahoo Finance
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
TG Therapeutics (NASDAQ: TGTX) director plans $274,794.08 stock sale - Stock Titan
TG Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference | TGTX Stock News - quiverquant.com
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - TG Therapeutics
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
TG Therapeutics at Cantor conference: briumvi gains momentum By Investing.com - Investing.com Canada
TG Therapeutics at Cantor conference: briumvi gains momentum By Investing.com - Investing.com India
TG Therapeutics at Cantor conference: briumvi gains momentum By Investing.com - Investing.com UK
TGTX: BRIUMVI targets $1B+ run rate, expanding with subQ and simplified dosing, backed by strong IP - TradingView
TG Therapeutics (TGTX) to Report Q2 Results: Wall Street Expects Earnings Growth - Eastern Progress
TG Therapeutics, Inc. (TGTX) Stock Analysis: Unveiling a 24.52% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
TGTX Stock On Track For Best Day In 3.5 Months Amid Fresh Buyout Rumors - Stocktwits
TG Therapeutics to Participate in the Cantor Global Healthcare Conference - manilatimes.net
TG Therapeutics to Participate in the Cantor Global Healthcare Conference - TG Therapeutics
TG Therapeutics to Participate in the Cantor Global Healthcare Conference - GlobeNewswire
B. Riley Securities Remains a Buy on TG Therapeutics (TGTX) - The Globe and Mail
(TGTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Tg Therapeutics Inc Azioni (TGTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tg Therapeutics Inc Azioni (TGTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Charney Laurence N | Director |
Sep 10 '26 |
Proposed Sale |
54.96 |
5,000 |
274,794 |
0 |
| Echelard Yann | Director |
Nov 24 '25 |
Sale |
32.57 |
5,000 |
162,850 |
223,816 |
| Echelard Yann | Director |
Nov 24 '25 |
Proposed Sale |
32.57 |
5,000 |
162,850 |
0 |
2.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):